Mylene Yao, M.D.

Digital health technologies: opportunities & challenges in rheumatology Daniel Solomon, MD MPH & Bob Rudin, PhD Abstract The past decade in rheumatology has seen tremendous innovation in digital health technologies, including the electronic health record, virtual visits, mobile health, wearable technology, digital therapeutics, artificial intelligence and machine learning. The increased availability of these technologies offers opportunities for improving important aspects of rheumatology, including access, outcomes, adherence and research. However, despite its growth in some areas, particularly with non-health-care consumers, digital health technology has not substantially changed the delivery of rheumatology care. This Review discusses key barriers and opportunities to improve application of digital health in rheumatology. Key topics include smart design, voice enablement and the integration of electronic patient-reported outcomes. Smart design involves active engagement with the end users of the technologies, including patients and clinicians through focus groups, user testing sessions and prototype review. Voice enablement using voice assistants could be critical for enabling patients with hand arthritis to effectively use smartphone apps and might facilitate patient engagement with many technologies. Tracking many rheumatic diseases requires frequent monitoring of #patientreportedoutcomes. Current practice only collects this information sporadically, and rarely between visits. #Digitalhealth technology could enable patient-reported outcomes to inform appropriate timing of face-to-face visits and enable improved application of treat-to-target strategies. However, best practice standards for digital health technologies do not yet exist. To achieve the potential of digital health technology in rheumatology, rheumatology professionals will need to be more engaged in the technology design process and provide leadership to effectively incorporate new tools into clinical care. Key points Digital health technology (DHT) offers enormous potential to improve rheumatology care but this potential has so far been largely unrealized. The #electronichealthrecord, virtual visits, mobile health, wearable technology, digital therapeutics, artificial intelligence and machine learning could all have a role individually and in combination to reshape rheumatology practice. Increased use of user-centred design in the development of #digitalrheumatology tools is needed and will facilitate electronic patient-reported outcomes becoming a cornerstone of rheumatology. https://lnkd.in/eEZCSEg7

3

1 Comment

Cancer Fragmentation, Multi-Cancer Detection & Liquid Biopsy Innovation at PMWC 2025 (Feb. 5-7), Santa Clara Convention Center in California. Liquid biopsy is reshaping oncology, enabling non-invasive insights into tumor biology, monitoring treatment response, and catching early signs of relapse. This approach is transforming staging, identifying therapeutic targets, and understanding resistance mechanisms, with clinical studies affirming its impact. Highlights on Feb 6th in Track 4 - Liquid Biopsy: 🔹 Keynotes: Early Cancer Detection with DELFI Technology - Victor Velculescu (Johns Hopkins) Circadian Rhythms & CTC Metastasis - Dr. Nicola Aceto (ETH Zurich) 🔹 Panels: --Innovative Approaches in Liquid Biopsy - Chaired by Victor Velculescu, featuring Adam Widman (MSKCC) --CTCs: The New Frontier - Chaired by Nicola Aceto, with Min Yu, (University of Maryland) & Matteo Ligorio (UTSW) --Improving Sensitivity of MRD and MCED - Chaired by Adrian Lee, with Jonathan Beer (BMS), C. Ola Landgren, M.D., Ph.D. (UMiami), & Marija Balic (UPMC) --Sequencing for Early Detection - Featuring Alex Sockell, PhD (PacBio), James Hadfield (AstraZeneca), & Cristian Tomasetti (City of Hope) --Innovations Across Cancer Continuum - Led by Tomasz (Tom) Beer (Exact Sciences), with Elizabeth O'Donnell, MD, DipABLM (Dana-Farber) & Arnaud PAPIN (Merck) --Multi-Cancer Early Detection - Chaired by Peter B. (DELFI Diagnostics), with Joshua Cohen (Haystack MRD™ by Quest Diagnostics®), Lauren C. Leiman (BLOODPAC), & Joshua Ofman MD, MSHS (GRAIL) --Showcase: Wendy Winckler (Droplet Biosciences, Inc), Varsha Rao (Claret Bioscience), Matthew Pink (Biodesix, Inc.), J.Carl Barrett (Precede Biosciences) 🌐 Join PMWC 2025 in Silicon Valley (Feb 5-7) to connect with oncology pioneers tackling the future of cancer care. 🔗 Register now to secure your place! https://lnkd.in/g9j9UnKS #PMWC25 #PrecisionMedicine #LiquidBiopsy #Oncology #CancerResearch #HealthcareInnovation PMWC - Precision Medicine World Conference, DeciBio, International Society of Liquid Biopsy #AACR24

40

🚨 Stanford Medicine researchers have discovered a novel compound that enhances naloxone's ability to combat potent opioids like fentanyl. This pioneering study reveals how the new compound, known as "compound 368," boosts naloxone's effects, potentially offering more enduring protection and milder withdrawal symptoms. This innovation could revolutionize the approach to tackling the fentanyl crisis, marking a significant step forward in public health. #HealthcareInnovation #OpioidCrisis #StanfordMedicine Read more: https://lnkd.in/eT3z-zbM

1

1 Comment

I was honored and privileged to be a guest on the The Incubator Podcast hosted by Benjamin Courchia MD and Daphna Barbeau alongside my good friend and colleague Ryan McAdams, MD (https://lnkd.in/g9y2DPcG). It was fun. In all honesty, I am an introvert and had for decades shied away from public speaking. Over the last decade as a physician leader, I have had to find my voice and work on my ability to speak (better)-- to provide a message (important). For me, the message has been this: -In #healthcare we should be doing better for our patients and their families -Doing Better for patients and families is not about using the newest technology or newest medicine ( see delayed cord clamping and caffeine in the neonatal ICU, cheap but very effective interventions). -It is about improving our teamwork. -It is about supporting our healthcare teams to work as safely and effectively as we can. -It is about learning from our errors, not hiding them-- creating a #JustCulture, which takes significant time and effort; One case review, One self-reporting error at a time with each seen as an opportunity to learn, not hide or blame. -It is about #UsingWhatWeHaveBetter -The Podcast conversation was about #AI--- is that not the shiniest, newest technology? Well yes, but it holds promise for us to use and learn from healthcare data which largely has sat idle in electronic health records captured as unstructured data in images, text, audio, video, streaming continuously from physiological monitors. -There will be important, never conceived of insights from these data. Some of which will be beneficial, some which will not be and maybe even be harmful, especially if we allow our bias embedded within healthcare data to be amplified with this new technology. The gap in inequities could widen. -We need clinicians and clinician scientists to be involved in the safe, effective, ethical, and unbiased application of AI in healthcare. It needs to be studied prior to widespread application. That is the platform that NeoMINDAI (https://lnkd.in/g4F--zeH) is creating for those interested in improving #perinatal, #neonatal, and #pediatric health and care. We are an open and collaborative group-- if you are interested you can find the contact link on our website and we can add you to our list serv.

25

5 Comments

Can AI match up to physicians? ChatGPT versus Resident Physicians — A Benchmark Based on Official Board Scores Groundbreaking research by Uriel Katz et el. compares the performance of large language models (LLMs), GPT-3.5 and GPT-4, against 849 resident physicians who took the 2022 Israeli medical specialist license examination. Key Takeaways: GPT-4 outperforms or matches many physicians in key disciplines: Psychiatry: Ranked in the 74th percentile, outperforming most physicians. General Surgery: Median 44th percentile, comparable to the median physician. Internal Medicine: Median 56th percentile, competitive with the median physician. In Pediatrics and OB/GYN, GPT-4 scored lower but still surpassed a significant fraction of physicians. GPT-3.5 struggled, failing to pass in all disciplines and performing below the majority of physicians. What’s the impact? This milestone highlights the growing capability of AI in medical applications. GPT-4's ability to pass residency exams in four of five disciplines underscores the maturity of LLM technology and its potential role in shaping the future of medical education and practice. The Big Picture: As AI evolves, its integration into healthcare may enhance decision-making, education, and patient care. However, these findings also raise important questions about the ethical, practical, and collaborative role of AI alongside human expertise. More to explore in NEJM AI: https://lnkd.in/dhp-j-qf What is your opinion on AI shaping the future of medicine?

58

4 Comments

Game-Changing Breakthrough in Pediatric Brain Cancer Therapy A Stanford Medicine clinical trial, co-led by Dr. Crystal Mackall and Dr. Michelle Monje, has achieved what was once thought impossible: a CAR-T cell therapy targeting GD2 protein has shown unprecedented success in treating diffuse midline gliomas, one of the deadliest childhood brain cancers. 💡 The Breakthrough: Target: GD2 protein on tumor cells, a novel approach for these aggressive cancers. Impact: 9 out of 11 children in the trial saw significant benefits, including tumor shrinkage and neurological improvement. Remarkable Outcome: One child’s tumor completely disappeared and has remained undetectable for four years post-treatment! This achievement marks a monumental leap in precision medicine, offering new hope for families facing these devastating diagnoses. 👉 Read more about this inspiring story: https://lnkd.in/gdN4UEfS At PMWC 2025 (Feb 5-7), we’re diving into similar innovations in Track 1, Gene and Cell Therapies in Oncology, co-hosted with Labcorp. This full-day agenda will feature sessions on cutting-edge advances, including mRNA vaccines and CAR T-cell therapies, chaired by Richard Klausner (Altos Labs), with esteemed speakers like Drew Weissman (Penn Medicine), Ira Mellman (formerly Genentech), and Crystal Mackall (Stanford). Next-generation ADCs led by Sandhya Girish (Gilead Sciences), Allogeneic cell therapy innovations with Elliot Norry (Adaptimmune), and stem cell and gene therapy breakthroughs chaired by Catriona Jamieson (UCSD Health). We’re proud to announce that Dr. Crystal Mackall will be honored with the PMWC Luminary Award at 9am on February 6th during Track 1. Dr. Mackall, the Ernest and Amelia Gallo Family Professor and Founding Director of the Stanford Center for Cancer Cell Therapy, has developed advancements in CAR-T cell therapy, including innovative clinical trials and improved treatment protocols that have significantly enhanced patient outcomes in pediatric oncology. 🗓️ Event Dates: February 5-7, 2025 📍 Location: Santa Clara Convention Center (~5 miles from the San Jose Airport) Join us! https://lnkd.in/gPtkWZbQ Carl June, Bita Sahaf, PhD, Liora Schultz, Sneha Ramakrishna, Anirban Maitra, Cynthia Campen, Laura Prolo, Steven Feldman, Jasia Mahdi, David Miklos, Allison Betof Warner, Michael Link, Ami Bhatt, Natalia Gomez-Ospina MD, PhD, Heather Wakelee, CARGO Therapeutics, Lyell Immunopharma, Mike O'Neill, PMWC - Precision Medicine World Conference, #PediatricCancer, #BrainCancer, #Oncology, #CAR_TCellTherapy, #GeneTherapy, #PrecisionMedicine, #PMWC25, #Labcorp, #MedicalInnovation, #StanfordMedicine,

62

"How to Live Longer" - reflecting on a fascinating discussion about the future of healthcare at the #newyorkerfest between Dr. Atul Gawande and Dr. Dhruv Khullar: A few key insights worth sharing: 💡 The future of medicine isn't just about living longer—it's about living better. We're finally recognizing that healthcare should align with patients' life priorities and values, not just survival metrics. 🔍 While maximum lifespan remains stubborn (~120 years), we're getting better at helping more people reach their 80s and 90s with quality of life. Countries like Japan and Korea are leading the way with 85-year average life expectancies. 📊 The power of accessible healthcare is striking: Thailand reduced deaths before age 50 from 60% to just 35% in 20 years by building strong primary care infrastructure and deploying community health volunteers. That's the difference good healthcare systems can make. 🌡️ Climate change is emerging as a major health crisis. From heat-related illnesses to changing disease patterns, our healthcare systems need to adapt quickly. ⚖️ The biggest challenge ahead? Healthcare equity. When our top 1% live to 89 while others barely reach 72, we have work to do. Countries succeeding in this space prioritize accessible primary care and community health workers. One measure Dr. Gawande uses in his work at USAID is % of people dying under the age of 50. This is what this measure looks like in different parts of the world: - Japan 2% - Europe -5%  - USA - 10%  - Africa - 65% #Healthcare #FutureOfMedicine #PublicHealth #HealthEquity #ClimateHealth

7

This is really good. One of the main challenges with longevity is the lack of clear criteria and standards to define what longevity is in practice. The pyramid make perfect sense from a practitioner perspective and also offers the individuals seeking healthier life a roadmap to follow. Great job everyone! Or Hever.

3

So many great people are dedicated to eradicating cancer, across so many industries. To make real progress, it’s going to take our collective talents, creativity, and a willingness to think outside the box (occasionally). 2.1 million cancer patients will be diagnosed here this year, and they don’t have time for politics, nihilism, or small thinking. It’s too late to save Daniel Flora MD, PharmD, or Dave Flora’s mom, Same for David Penberthy and Scott Penberthy. We must do better. My call to action as so many of us are thinking about moms lost: take a step today to get involved, and do what you can to help us get there. That means ACTIVELY supporting more advocacy, research, screening and prevention, anywhere you can. Solid progress is being made, but so much left to do. Fighting cancer is a team sport. Some easy steps: Join American Cancer Society Cancer Action Network (ACS CAN): https://lnkd.in/gWhKQ78c Engage with Association of Cancer Care Centers: https://lnkd.in/g4tXF29i Support American Cancer Society events, fundraise, spread the information they share on here w your networks: https://lnkd.in/gG5sUZK4 Please add any organizations you think we should be following or supporting that are near and dear to you in the comments below. #brothersfigtingcancer Sanjay Juneja, M.D. Olalekan Ajayi PharmD MBA FACCC AI in Precision Oncology Mary Ann Liebert, Inc. St. Elizabeth Healthcare St. Elizabeth Physicians

77

14 Comments

Some good reads in the August 23, 2024 issue of Science Magazine - Wafik S. El-Deiry, MD, PhD, FACP The National Institutes of Health Monica Bertagnolli WIN Consortium in cancer personalized medicine https://lnkd.in/ex3knSFy #OncoDaily #Oncology #Cancer #Health #Medicine #ClinicalTrials #HealthCare

27

I started a "CHIP Clinic" to evaluate and manage risk in people found to have clonal hematopoiesis of indeterminate potential (CHIP) 3 generations of great fellows ago. I worked first with Amy Lin, then with Aeron Small, and now with Ohad Oren as fellows to see these people. As CHIP is a newly recognized phenomenon, there has been a deficit in educational materials for people with CHIP. We offer this "Patient Page" just published in JAMA Cardiology to fill this gap. #heartdisease #heartattack #heartfailure #myocardialinfarction #clonalhematopoiesis #cardiology #riskfactors #cardiooncology #thrombosis #bloodclots #somaticmutations

488

20 Comments

Our Founder and CSO, Quin Wills, recently joined the American Association for the Study of Liver Diseases (AASLD) in San Diego, for one of the biggest annual gatherings in hepatology. AASLD is renowned for presenting the latest advancements in hepatology, from foundational science to impactful clinical trials. Here are some of Quin's key takeaways ⬇️ 🔸 Madrigal is paving the way for F2/F3 MASH treatments, setting the stage for future therapies with better efficacy to meet unmet needs in later-stage patients. 🔸 GLP1 and incretin therapies are showing strong results in resolving steatohepatitis, raising the bar for new MASH treatments. 🔸 Human-relevant fibrosis modelling, including regeneration and disease regression, remains a significant challenge for the industry. Missed the conference? Feel free to reach out with any questions or drop Quin a comment below!

15

Build Your Family in Iran ‍‍‍  Struggling with infertility? You don't have to go it alone. Iran is a global leader in advanced fertility treatments, offering options like IUI, IVF, ICSI, and more. Dr. Ali Bazazi, a fertility consultant, joins us to discuss these options and how they can help you achieve your dream of parenthood.  In this video, we explore:  Advanced fertility treatments in Iran like IUI, IVF, ICSI  Third-party services including egg donation and surrogacy  Genetic testing options like PGS/PGTA If you're considering fertility treatment, watch this video to learn more about the possibilities available in Iran #infertility #fertilitytreatment #iran #IUI #IVF #ICSI #eggdonation #surrogacy #PGS #PGTA #familybuilding #buildyourfamily

22

The most fascinating thing about this study is that difference in weight loss between semaglutide group and placebo group was only 6%. That is pretty small difference for an expensive intervention. Clearly, there are other non-weight loss benefits but those are also moderate at best from number to treat perspective. More and more data is showing that in real world scenarios achieving meaningful weight loss in complex populations is not a walk in the park. Well designed study!

15

1 Comment

There's a new available technology ready just in time for the the New Year, marked by Rosh Hashana. 🍎 Prof. Haitham Amal and his research team at The Hebrew University of Jerusalem have developed two groundbreaking molecules HU-40 and HU-41, targeting key pathways in Bipolar Disorder. Tested on patient-specific iPSC-derived neurons, these molecules offer a personalized, precision medicine approach that addresses core dysfunctions in BD and holds potential for improved efficacy and safety over current treatments. Overall, Prof. Amal has also received a $17M grant to continue pursuing his research, underscoring the significance and promise of his work in mental health therapeutics. With the global BD therapeutics market expected to reach $6.9 billion by 2027, these novel therapies could be game-changers for treatment-resistant patients. Read more: https://heyor.ca/lif0fb If you would like to support this technology, please contact the Business Development representative Ariela Markel at [email protected]. #BipolarDisorder #MentalHealth #BioTech

44

5 Comments